News | August 12, 2024
Novo Nordisk's H1 sales increased by 24% in Danish kroner
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The inspection was concluded with zero observations
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
Subscribe To Our Newsletter & Stay Updated
